Gene expression and protein level analysis suggests a protective upregulation of alternative BCL-2 prosurvival proteins in response to BH3 mimetic single-treatment in BP-CML. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.